Scalper1 News
Two top-rated midsized drugmakers delivered sharply different third-quarter reports Tuesday, sending their stocks in opposite directions. Jazz Pharmaceuticals (JAZZ), reporting after the close, said earnings rose 31% over the year-earlier quarter to $2.33 a share, beating the consensus view by 11 cents, according to Thomson Reuters. Sales climbed 32% to $306.6 million, about $4 million above analysts’ estimates. The company Scalper1 News
Scalper1 News